Recombinant human TSH and radioactive therapy in the management of benign multinodular goiter.
Eur J Endocrinol. 2014 Sep 4
Rani D, Kaisar S, Awasare S, Kamaldeep, Abhyankar A, Basu S.
Examining recombinant human TSH primed (131)I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1767-80.
Pryma DA, Mandel SJ.
Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies.
J Nucl Med. 2014 Sep;55(9):1485-1491.
Arce MB, Molina TC, Hernández TM, de la Cinta Calvo Morón M, Herrero CH, De La Riva Pérez PA, Montaño JC.
Thymic uptake after high-dose I-131 treatment in patients with differentiated thyroid carcinoma: A brief review of possible causes and management.
Endocrinol Nutr. 2014 Aug 23.
Kist JW, de Keizer B, Stokkel MP, Hoekstra OS, Vogel WV; THYROPET study group.
Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.
BMC Cancer. 2014 Jun 5;14:405.
Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek M, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AG, Fugazzola L, Chiti A.
Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
J Endocrinol Invest. 2014 May 21
Fu H, Ma C, Tang L, Wu F, Liu B, Wang H.
Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta analysis.
Q J Nucl Med Mol Imaging. 2014 May 21.
Markovina S, Grigsby PW, Schwarz JK, DeWees T, Moley JF, Siegel BA, Perkins SM.
Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence.
Thyroid. 2014 Jul;24(7):1121-6.
Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi SR.
Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature.
Int J Endocrinol Metab. 2014 Apr 1;12(2):e14424.
Hyposalivation: the roles of radioactive iodine and stapes surgery.
J Oral Maxillofac Surg. 2013 Feb;71(2):e76-80.
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK.
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):61-71.
Rapkin L, Pashankar FD.
Management of thyroid carcinoma in children and young adults.
J Pediatr Hematol Oncol. 2012 May;34 Suppl 2:S39-46.
Wong KK, Dvorak RA, Marzola MC, Grassetto G, Gross MD, Rubello D.
Molecular imaging in the management of thyroid cancer.
Q J Nucl Med Mol Imaging. 2011 Oct;55(5):541-59.
Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A.
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2267-76.
Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A.
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2298-306.
Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D.
ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1251-4.